Ammonia N-13
Autonomic Nervous System Disorder
Explore 11 assets in Autonomic Nervous System Disorder →Floatz Rating
D30/100
Confidence
Indicative
Sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Modality
Small molecule
Development Phase
Unknown
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03648905CT.gov Clinical Laboratory Evaluation of Chronic Autonomic Failure | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Autonomic Nervous System Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ammonia N-13 (this asset) | National Institute of Neurological Disorders and Stroke (NINDS) | Unk | D · 30 |
| Droxidopa | Vanderbilt University Medical Center | P1/2 | CCC |
| Carbidopa | Daniel Claassen | P1/2 | CCC |
| Entacapone | Daniel Claassen | P1/2 | CCC |
| Midodrine | Vanderbilt University Medical Center | P1 | CCC |
| Fezolinetant | Shehzad Basaria, M.D. | P2 | CCC |
| FDOPA | Daniel Claassen | P1 | CC |
| (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone | Zagazig University | N/A | D |
| 6-(18F)-FLUORODOPAMINE | National Institute of Neurological Disorders and Stroke (NINDS) | Unk | D |
+4 more in the Autonomic Nervous System Disorder cohort
Other indications for Ammonia N-13
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Sickle Cell Disease | — | P2 | CCC · 48 |
| Pure Autonomic Failure | — | Unk | D · 30 |
| Multiple System Atrophy | — | Unk | D · 30 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ammonia N-13 in Autonomic Nervous System Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ammonia-n-13-autonomic-nervous-system-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →